Newsroom

In our Newsroom we share some recent headlines and links to articles that may be of interest to our bleeding and clotting disorder patients, families, and providers.
NewsPink

Be Biopharma Secures Financing to Advance Hemophilia B Treatment BE-101

January 17, 2025

Be Biopharma has raised $92 million in series C financing to support the first in-human Phase 1/2 trial of BE-101, the company's B-cell therapy candidate for hemophilia B. The treatment is designed to use a patient's own immune B-cells, genetically modify them, and infuse them back into the patient. 

vwdnews

FDA Grants Fast Track Designation to Star Therapeutics' VWD Therapy

January 10, 2025

The US FDA has granted Fast Track designation to the investigational von Willebrand disease (VWD) therapy VGA039. The therapy is a subcutaneously-delivered monoclonal antibody therapy designed to target Protein S as a means of restoring proper blood clotting in people with all types of VWD. 

GeneTherapyResearch6

Phase 3 Gene Therapy Trial Shows Giroctocogene Fitelparvovec Safe, Effective

December 13, 2024

Nearly two-thirds of hemophilia A patients given a single infusion of the investigational gene therapy giroctocogene fitelparvovec were free of bleeding episodes almost three years after treatment. The data from the phase 3 AFFINE clinical trial was shared at a presentation given at the American Society of Hematology (ASH) annual meeting.

GeneTherapyResearchPink1

Investigational Hemophilia A Gene Therapy Updates Shared at ASH

December 13, 2024

Expression Therapeutics announced phase 1 clinical trial results based on ET3, the company's investigational gene therapy. It is a therapy developed with novel lentiviral vectors. The therapy uses repurposed retroviruses to introduce factor VIII transgene to deliver targeted genetic material.

NewsTurqPurple

Potential Hemophilia Treatment SerpinPC Halted by Centessa

November 15, 2024

Centessa Pharmaceuticals has discontinued their clinical development of their experimental under-the-skin therapy SerpinPC. The therapy was found safe and well tolerated in a recent trial, but the company decided to focus their investments on other areas after Pfizer's Hympavzi, which used a similar mechanism, was approved by the FDA.

NewsRed1

Study Finds Missing Clotting Proteins in Hemophilia Patients Can Directly Affect Bone Health

November 8, 2024

A recent study from Italy shows new findings on why bone problems are a common issue among hemophilia patients. The study looked at missing clotting proteins and compared experiments on cells gathered from healthy donors and hemophilia patients. 

ResearchYellow

Study Shows Sevenfact Safe, Effective for Patients with Hemophilia A or B with Inhibitors

October 18, 2024

A real world study showed that eptacog beta, known as Sevenfact, was deemed safe and effective at stopping bleeds in patients with hemophilia A or B that also have inhibitors. The bypassing agent was shown to be 96% effective at resolving symptoms and controlling bleeds. 

FDAApprovedBlue

FDA Approves First Non-Factor, Once-Weekly Treatment for Hemophilia A or B

October 11, 2024

The US Food and Drug Administration approved Hympavzi (marstacimab-hncq) for routine prophylaxis to prevent or reduce frequency of bleeding episodes in adult and pediatric patients 12 and over. The treatment is designed to treat both hemophilia A and B as it targets a protein in the blood clotting process.

ResearchGreen2b

Study Suggests Hemlibra Effectively Prevents Bleeding in Acquired Hemophilia A

October 1, 2024

According to a real-world study in Japan, Hemlibra effectively prevented bleeds in patients with acquired hemophilia A. The study compared outcomes of patients with acquired hemophilia A who were treated with Hemlibra, and those who were not, finding those in the Hemlibra group had significantly less bleeding.

ResearchPurpleTurq

Survey Finds Most Men With Hemophilia Continue to Have Joint Problems Even With Prophylaxis

September 13, 2024

In a survey of doctors, researchers found that nearly two-thirds of men with moderate or severe hemophilia A have joint problems that cause pain and reduce quality of life, even when they are on factor replacement therapy to reduce bleeding. The data showed that joint problems still represent a burden in the care of these patients. 

NewsYellow

Gene Editing Therapy Shows Promise in Pre-clinical Study in Animals

September 6, 2024

A gene editing therapy being developed by Metagenomi for hemophilia A has shown safety and durability in an ongoing pre-clinical study in three non-human primates. The results showed that after a year, two animals had normal or nearly normal factor levels. The third animal had factor levels in the mild hemophilia range.

GeneTherapyResearch7green

Gene Therapy Data for Roctavian Shows Most Remained Off Preventative Therapy After Seven Years

August 20, 2024

A single dose of the gene therapy Roctavian (valoctocogene roxaparvovec-rvox) nearly zeroed out the number of bleeds and need for prophylaxis for as long as seven years. This is the longest follow-up to date for any hemophilia A gene therapy clinical trial.

 

News Content Disclaimer:

Links to articles listed may take readers to websites separate and out of the control of the CU School of Medicine and the Hemophilia and Thrombosis Center. The CU School of Medicine and the Hemophilia and Thrombosis Center are not responsible for any errors, inaccuracies or opinions that may be expressed in any of the linked articles.

Looking for an older article?

Previous articles featured on our website can be found at our archive page here. Please note that links in our archive files may take readers to websites that may have changed their link. In some cases these links do not work anymore. We periodically check and remove articles that have broken links. If you have questions about these articles, please contact us at hemophilia@ucdenver.edu.

CMS Login